Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the merged, public company.

Launched in 2019 with $65 million from Versant Ventures, Apple Tree Partners and Samsara Capital, Chinook Therapeutics Inc. brings to the union preclinical rare disease therapy CHK-336 and clinical asset atrasentan for IgA nephropathy and other primary glomerular diseases (see “Chinook Reels In Series A”)...